EUCTR2020-004047-86-ES进行中（未招募）1 期
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALPN-101 IN SYSTEMIC LUPUS ERYTHEMATOSUS
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 130
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent
- •Age 18 to 65
- •Diagnosis of lupus for = 6 months prior to Screening
- •Positive ANA and/or elevated anti-dsDNA and/or elevated anti-Smith antibody test at Screening
- •Active lupus at Screening and Baseline, as defined per-protocol and confirmed by the study's medical monitor
- •Standard lupus medications must be stable prior to Screening
- •Women must have a PAP smear and known HPV status within 12 months of Day 1
- •All participants must use highly effective birth control if they/their partner are capable of becoming pregnant
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 130
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Life-threatening or organ system-threatening lupus activity that is anticipated to require increased treatment during the study
- •Proteinuria consistent with nephrotic syndrome
- •Active lupus-related neuropsychiatric disease
- •Drug-induced lupus
- •Any serious health condition that would place the subject at undue risk from the study or would confound interpretation of safety or efficacy outcomes
- •Recent or serious ongoing infection; risk or history of serious infection
- •Receipt of live vaccination within 8 weeks of Day 1, or expected to require live vaccination during the study
- •Unacceptable Screening laboratory results
- •History of new, ongoing, or recurrent malignancy <= 5 years prior to Day 1, with some exceptions per-protocol
- •Pregnant or breastfeeding at the time of screening, or plans to become pregnant <= 3 months following the last dose of study drug
- •Prior diagnosis of, or fulfills diagnostic criteria for, another rheumatic disease that overlaps with lupus or another autoimmune or inflammatory disease that may confound clinical assessments or increase subject risk in the study
- •Diagnosis of, or fulfills diagnostic criteria for, fibromyalgia
- •Functional class IV lupus
- •Does not meet protocol washout periods for concomitant medications
- •Serious lupus disease activity, which warrants immediate immunosuppressive therapy not appropriate for the study or which makes the possibility of receiving placebo or investigational agent an inappropriate risk
- •Ongoing participation in another therapeutic clinical trial
- •Known hypersensitivity to ALPN-101, components thereof, or excipients contained in the drug formulation
研究者
相似试验
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-HURegeneron Pharmaceuticals, Inc.803
进行中（未招募）
1 期
A clinical trial to assess the efficacy and safety of Nemolizumab (CD14152) compared to placebo in patients with Atopic Dermatitis.MedDRA version: 21.1Level: LLTClassification code 10003639Term: Atopic dermatitisSystem Organ Class: 100000004858Atopic DermatitisEUCTR2019-001888-75-BEGalderma S.A.750
进行中（未招募）
1 期
An Efficacy and Safety Study of Alirocumab in Children and Adolescents with Heterozygous Familial HypercholesterolemiaHypercholesterolaemiaMedDRA version: 20.0Level: PTClassification code 10020603Term: HypercholesterolaemiaSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2017-001903-60-NOSanofi-aventis recherche & développement500
进行中（未招募）
1 期
A Study to Evaluate ESK-001 in Patients with PsoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: PTClassification code 10037153Term: PsoriasisSystem Organ Class: 10040785 - Skin and subcutaneous tissue disordersEUCTR2022-002633-34-CZAlumis Inc.210
进行中（未招募）
1 期
Evaluating the Efficacy and Safety of BG00011 in Participants with Idiopathic Pulmonary Fibrosismild to moderate Idiopathic Pulmonary FibrosisMedDRA version: 21.1Level: PTClassification code 10021240Term: Idiopathic pulmonary fibrosisSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-003158-18-ITBIOGEN IDEC RESEARCH LIMITED106